Literature DB >> 2153803

Imidazoline-guanidinium receptive site in renal proximal tubule: asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance.

I Coupry1, D Atlas, R A Podevin, I Uzielli, A Parini.   

Abstract

In the present report we have used [3H]idazoxan to characterize the rabbit renal imidazoline preferring site by defining its plasmalemma distribution, its regulation by cations and the type of interaction with the clonidine displacing substance (CDS), a putative endogenous ligand for the imidazoline receptor. The density of [3H]idazoxan binding sites was 12-fold higher in purified basolateral membranes than in brush-border membranes (maximal binding activity, 566 +/- 118 vs. 46 +/- 2 fmol/mg of protein). In basolateral membranes, [3H]idazoxan binding was inhibited not only by imidazoline compounds but also by guanidinium analogs such as guanabenz, amiloride, 5-(M-ethyl-N-isopropyl)amiloride and phenamylamiloride. Amiloride had no effect on the dissociation rate of [3H]idazoxan, suggesting a direct interaction of this molecule with the ligand binding site. [3H]Idazoxan binding was 80% inhibited by 150 mM K+ or Rb+. The effect of K+ appeared to occur through the interaction with an allosteric site in as much as both the apparent dissociation constant and the dissociation rate of [3H]idazoxan were increased in the presence of 75 mM K+. CDS inhibited [3H]idazoxan binding with a half-maximal effective concentration of 2 U/250 microliters. The competitive nature of CDS effect was indicated by the increase in the apparent dissociation constant of [3H]idazoxan (Kd from 3 +/- 0.3 to 8.5 +/- 0.2 nM, P less than .01) in the presence of CDS. In conclusion, our findings showed that the imidazoline-guanidinium receptive site is located mainly in the basolateral side of the tubular cell, recognizes CDS and is regulated by K+.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153803

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.

Authors:  Yonghua Zhang; Harold K Kimelberg
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

3.  Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery.

Authors:  G J Molderings; F Hentrich; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

4.  The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain.

Authors:  G Olmos; R Alemany; P V Escriba; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

5.  Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain.

Authors:  N J Mallard; A L Hudson; D J Nutt
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

6.  Effects of imidazolines on noradrenaline release in rat isolated kidney.

Authors:  C Bohmann; P Schollmeyer; L C Rump
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-02       Impact factor: 3.000

7.  [3H]-RS-45041-190: a selective high-affinity radioligand for I2 imidazoline receptors.

Authors:  A C MacKinnon; W S Redfern; C M Brown
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

8.  Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-adrenoceptors.

Authors:  R G Evans; W P Anderson
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

9.  LNP 906, the first high-affinity photoaffinity ligand selective for I1 imidazoline receptors.

Authors:  Dragan Urosevic; Urosevic Dragan; Stephan Schann; Schann Stephan; Jean-Daniel Ehrhardt; Ehrhardt Jean-Daniel; Pascal Bousquet; Bousquet Pascal; Hugues Greney; Greney Hugues
Journal:  Br J Pharmacol       Date:  2004-06       Impact factor: 8.739

10.  Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function.

Authors:  S Diamant; T Eldar-Geva; D Atlas
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.